scholarly journals Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases

2002 ◽  
Vol 61 (9) ◽  
pp. 842-846 ◽  
Author(s):  
M Kuwana
Keyword(s):  
Systemic Sclerosis ◽  
Autoimmune Diseases ◽  
Autoantibody Response

scholarly journals Systemic sclerosis and microscopic polyangiitis after systemic exposure to silicone

2021 ◽  
Author(s):  
Claudia Carrera Muñoz ◽  
Jorge González Rodríguez ◽  
Annabel Abó Rivera ◽  
Elena Estarán ◽  
Jordi Roig Cárcel ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Autoimmune Diseases ◽  
Microscopic Polyangiitis ◽  
Systemic Exposure ◽  
Breast Implants ◽  
Inflammatory Syndrome ◽  
The Relationship

Abstract The relationship between silicon breast implants (SBIs) and autoimmune/inflammatory syndrome induced by adjuvants (ASIA) has been extensively analysed, with discordant results. We present a 45-year-old woman with confirmed systemic exposure to SBI who developed systemic sclerosis (SSc) followed by anti-neutrophil cytoplasmic antibody anti-myeloperoxidase vasculitis with renopulmonary syndrome. The novelty of our case is, first, confirmation of systemic exposure to SBI and, second, chronologic development of not one, but two severe autoimmune diseases. Controversy may still remain regarding SBIs and ASIA because it is unclear that previous studies confirmed systemic exposure to silicon in their cohort of patients.

scholarly journals Familial risk of systemic sclerosis and co-aggregation of autoimmune diseases in affected families

2016 ◽  
Vol 18 (1) ◽  
Author(s):  
Chang-Fu Kuo ◽  
Shue-Fen Luo ◽  
Kuang-Hui Yu ◽  
Lai-Chu See ◽  
Weiya Zhang ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Autoimmune Diseases ◽  
Familial Risk

scholarly journals New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis

Antibodies ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 12
Author(s):  
Roberto Lande ◽  
Raffaella Palazzo ◽  
Anna Mennella ◽  
Immacolata Pietraforte ◽  
Marius Cadar ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Early Diagnosis ◽  
Antibody Response ◽  
Allelic Variant ◽  
The Other ◽  
Autoantibody Response ◽  
Autoimmune Condition ◽  
Early Systemic Sclerosis ◽  
Systemic Sclerosis Patient

Chemokine (C-X-C motif) ligand 4 (CXCL4) is a biomarker of unfavorable prognosis in Systemic Sclerosis (SSc), a potentially severe autoimmune condition, characterized by vasculitis, fibrosis and interferon (IFN)-I-signature. We recently reported that autoantibodies to CXCL4 circulate in SSc patients and correlate with IFN-α. Here, we used shorter versions of CXCL4 and CXCL4-L1, the CXCL4 non-allelic variant, to search for autoantibodies exclusively reacting to one or the other CXCL4 form. Moreover, to address whether anti-CXCL4/CXCL4-L1 antibodies were present before SSc onset and predicted SSc-progression, we longitudinally studied two VEDOSS (Very Early Diagnosis of Systemic Sclerosis) patient cohorts, separating SSc-progressors from SSc-non-progressors. We found that anti-CXCL4-specific autoantibodies were present in both SSc and VEDOSS patients (both SSc-progressors and SSc-non-progressors). Anti-CXCL4-L1-specific autoantibodies were especially detected in long-standing SSc (lsSSc). Anti-CXCL4/CXCL4-L1 antibodies correlated with IFN-α and with specific SSc-skin features but only in lsSSc and not in early SSc (eaSSc) or VEDOSS. Thus, a broader antibody response, with reactivity spreading to CXCL4-L1, is characteristic of lsSSc. The early anti-CXCL4 autoantibody response seems qualitatively different from, and likely less pathogenic than, that observed in advanced SSc. Lastly, we confirm that anti-CXCL4 autoantibodies are SSc-biomarkers and uncover that also CXCL4-L1 becomes an autoantigen in lsSSc.

Systemic sclerosis in a patient with turner syndrome: A case report and a review of associated autoimmune diseases

2021 ◽  
Author(s):  
Ripalta Colia ◽  
Natalia Mansueto ◽  
Addolorata Corrado ◽  
Cinzia Rotondo ◽  
Francesco Paolo Cantatore
Keyword(s):  
Case Report ◽  
Systemic Sclerosis ◽  
Autoimmune Diseases ◽  
Turner Syndrome

scholarly journals Natural Killer Cells: Potential Biomarkers and Therapeutic Target in Autoimmune Diseases?

2021 ◽  
Vol 12 ◽  
Author(s):  
Elena Gianchecchi ◽  
Domenico V. Delfino ◽  
Alessandra Fierabracci
Keyword(s):  
Systemic Sclerosis ◽  
Autoimmune Diseases ◽  
Cytotoxic Activity ◽  
Nk Cells ◽  
Natural Killer ◽  
T Cell Activation ◽  
Cell Activation ◽  
Nk Cell ◽  
Killer Cell

Autoimmune diseases recognize a multifactorial pathogenesis, although the exact mechanism responsible for their onset remains to be fully elucidated. Over the past few years, the role of natural killer (NK) cells in shaping immune responses has been highlighted even though their involvement is profoundly linked to the subpopulation involved and to the site where such interaction takes place. The aberrant number and functionality of NK cells have been reported in several different autoimmune disorders. In the present review, we report the most recent findings regarding the involvement of NK cells in both systemic and organ-specific autoimmune diseases, including type 1 diabetes (T1D), primary biliary cholangitis (PBC), systemic sclerosis, systemic lupus erythematosus (SLE), primary Sjögren syndrome, rheumatoid arthritis, and multiple sclerosis. In T1D, innate inflammation induces NK cell activation, disrupting the Treg function. In addition, certain genetic variants identified as risk factors for T1D influenced the activation of NK cells promoting their cytotoxic activity. The role of NK cells has also been demonstrated in the pathogenesis of PBC mediating direct or indirect biliary epithelial cell destruction. NK cell frequency and number were enhanced in both the peripheral blood and the liver of patients and associated with increased NK cell cytotoxic activity and perforin expression levels. NK cells were also involved in the perpetuation of disease through autoreactive CD4 T cell activation in the presence of antigen-presenting cells. In systemic sclerosis (SSc), in addition to phenotypic abnormalities, patients presented a reduction in CD56hi NK-cells. Moreover, NK cells presented a deficient killing activity. The influence of the activating and inhibitory killer cell immunoglobulin-like receptors (KIRs) has been investigated in SSc and SLE susceptibility. Furthermore, autoantibodies to KIRs have been identified in different systemic autoimmune conditions. Because of its role in modulating the immune-mediated pathology, NK subpopulation could represent a potential marker for disease activity and target for therapeutic intervention.

Coexistence of systemic sclerosis with other autoimmune diseases

2006 ◽  
Vol 27 (4) ◽  
pp. 407-410 ◽  
Author(s):  
Paola Caramaschi ◽  
Domenico Biasi ◽  
Alessandro Volpe ◽  
Antonio Carletto ◽  
Melissa Cecchetto ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Autoimmune Diseases

scholarly journals Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients—High Efficacy of Rituximab

2022 ◽  
Vol 12 ◽  
Author(s):  
Michael Gernert ◽  
Hans-Peter Tony ◽  
Matthias Fröhlich ◽  
Eva Christina Schwaneck ◽  
Marc Schmalzing
Keyword(s):  
Stem Cell ◽  
Systemic Sclerosis ◽  
Lung Function ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Autoimmune Diseases ◽  
Cell Transplantation ◽  
Treatment Option ◽  
Hematopoietic Stem

BackgroundSystemic sclerosis (SSc) patients often need immunosuppressive medication (IS) for disease control. If SSc is progressive despite IS, autologous hematopoietic stem cell transplantation (aHSCT) is a treatment option for selected SSc patients. aHSCT is effective with good available evidence, but not all patients achieve a treatment-free remission after aHSCT. Thus far, data about the need of IS after aHSCT in SSc is not published. The aim of this study was to investigate the use of IS after aHSCT, its efficacy, and the occurrence of severe adverse events (SAEs).MethodsTwenty-seven patients with SSc who had undergone aHSCT were included in this single-center retrospective cohort study. Clinical data, including IS, SAEs, and lung function data, were collected.ResultsSixteen of 27 (59.3%) patients received IS after aHSCT. Methotrexate, rituximab, mycophenolate, cyclophosphamide, and hydroxychloroquine were most commonly used. The main reason for starting IS was SSc progress. Nine patients received rituximab after aHSCT and showed an improvement in modified Rodnan skin score and a stabilization of lung function 2 years after rituximab. SAEs in patients with IS after aHSCT (50.0%) were not more common than in patients without IS (54.6%). SAEs were mostly due to SSc progress, secondary autoimmune diseases, or infections. Two deaths after aHSCT were transplantation related and three during long-term follow-up due to pulmonary arterial hypertension.ConclusionDisease progression and secondary autoimmune diseases may necessitate IS after aHSCT in SSc. Rituximab seems to be an efficacious treatment option in this setting. Long-term data on the safety of aHSCT is reassuring.

scholarly journals Demyelinating Syndrome in Systemic Sclerosis and Neuromyelitis Optica

2019 ◽  
Author(s):  
khaled Deeb ◽  
Jessika Eby ◽  
Jose Labault-Santiago
Keyword(s):  
Systemic Sclerosis ◽  
Autoimmune Diseases ◽  
Neuromyelitis Optica ◽  
Rna Polymerase Iii ◽  
Clinical Manifestations ◽  
Transverse Myelitis ◽  
Clinical Findings ◽  
Therapeutic Interventions ◽  
High Dose ◽  
Scleroderma Renal Crisis

Abstract INTRODUCTION: The objective of this study is to report a case of a 44-year-old female who presented with intractable hiccups, vomiting, and later complicated with paraplegia. Imaging and sero/immunological studies were consistent with Neuromyelitis Optica (NMO) based on NMO-IgG sero-positivity and transverse myelitis on MRI. Further investigation revealed positive ANA, anti-RNA polymerase III autoantibodies, and Scl-70, leading to a concurrent diagnosis of systemic sclerosis (SSc). The coexistence of these two disease processes, namely systemic sclerosis and neuromyelitis optica, and their underlying clinical manifestations and therapeutic interventions, are seldom reported in literature and are worth reporting. CASE REPORT: The patient was treated with high dose steroids, and subsequently developed malignant hypertension and acute renal failure, later identified as steroid induced scleroderma renal crisis on renal biopsy. Although Neuromyelitis Optica spectrum disorder (NMOSD) has often been associated with various collagen and autoimmune diseases, the coexistence of NMOSD and SSc presented a challenge where patient underwent aggressive physical therapy and necessitated an intervention with Rituximab to achieve an appropriate clinical response. We have received consent forms from the participant in our study, and we have them on file in case they are requested. We have also received patient’s consent for the data presented in this article and Figure 1. CONCLUSION: This report expands on NMOSD associated autoimmune diseases. Systemic Sclerosis is an insidious disease that is often diagnosed late as not all patients often report skin manifestation. The finding suggests that patients presenting with acute neurological manifestations get tested for NMO-IgG/AQP-4 antibodies and other immunological studies based on clinical findings.

Sign in / Sign up

Export Citation Format

Share Document